Drug Profile
Ataciguat - Rancho Santa Fe Bio
Alternative Names: 1766; Ataciguat - RSF Bio; HMR 1766Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Rancho Santa Fe Bio
- Class Anthranilic acids; Benzamides; Cardiovascular therapies; Chlorobenzenes; Morpholines; Small molecules; Sulfonamides; Thiophenes
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Aortic valve stenosis
- Preclinical Unspecified
Most Recent Events
- 23 Jun 2021 Ataciguat - Rancho Santa Fe Bio is available for licensing as of 23 Jun 2021. https://rsfbio.com/
- 23 Jun 2021 Discontinued - Phase-II for Neuropathic pain in Europe (PO)
- 23 Jun 2021 Discontinued - Phase-II for Peripheral arterial occlusive disorders in Europe (PO)